- Home
- GCTK vs ACXP Comparison
GCTK vs ACXP Comparison
Compare GCTK & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GCTK
- ACXP
- Stock Information
- Founded
- GCTK 2001
- ACXP 2017
- Country
- GCTK United States
- ACXP United States
- Employees
- GCTK N/A
- ACXP N/A
- Industry
- GCTK Medical/Dental Instruments
- ACXP Biotechnology: Pharmaceutical Preparations
- Sector
- GCTK Health Care
- ACXP Health Care
- Exchange
- GCTK Nasdaq
- ACXP Nasdaq
- Market Cap
- GCTK 5.9M
- ACXP 6.8M
- IPO Year
- GCTK N/A
- ACXP 2021
- Fundamental
- Price
- GCTK $6.46
- ACXP $5.06
- Analyst Decision
- GCTK
- ACXP Strong Buy
- Analyst Count
- GCTK 0
- ACXP 3
- Target Price
- GCTK N/A
- ACXP $143.67
- AVG Volume (30 Days)
- GCTK 81.7K
- ACXP 1.7M
- Earning Date
- GCTK 11-14-2025
- ACXP 11-12-2025
- Dividend Yield
- GCTK N/A
- ACXP N/A
- EPS Growth
- GCTK N/A
- ACXP N/A
- EPS
- GCTK N/A
- ACXP N/A
- Revenue
- GCTK N/A
- ACXP N/A
- Revenue This Year
- GCTK N/A
- ACXP N/A
- Revenue Next Year
- GCTK N/A
- ACXP N/A
- P/E Ratio
- GCTK N/A
- ACXP N/A
- Revenue Growth
- GCTK N/A
- ACXP N/A
- 52 Week Low
- GCTK $4.22
- ACXP $3.80
- 52 Week High
- GCTK $2,928.00
- ACXP $38.00
- Technical
- Relative Strength Index (RSI)
- GCTK 47.05
- ACXP 39.73
- Support Level
- GCTK $6.35
- ACXP $6.24
- Resistance Level
- GCTK $6.60
- ACXP $6.80
- Average True Range (ATR)
- GCTK 0.43
- ACXP 0.51
- MACD
- GCTK -0.09
- ACXP -0.31
- Stochastic Oscillator
- GCTK 14.72
- ACXP 5.15
About GCTK GlucoTrack Inc.
GlucoTrack Inc is a medical device company. It is focused on defining novel approaches that make diabetes management more accurate and convenient for daily living. The company has developed the GlucoTrack model that measures real-time blood glucose levels. The Company is developing an long-term implantable continuous blood glucose monitoring (CBGM) system, built on healthcare technologies. It is designed to meet the critical needs of insulin-dependent individuals or those at risk of hypoglycemia in the U.S.
About ACXP Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.